TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05608863

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle - group sessions
Description: The Combined Lifestyle Intervention Program consists of a total of 7 individual coaching sessions and 16 group sessions in a 2 year program. The individual coaching sessions will be done in a virtual setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle - individual coaching
Description: The Individual Intervention consists of a total of 7 individual coaching sessions in a 2 year program and additional written information. These will be done in a virtual setting.
Study: NCT03235232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BREMEN eye drops
Description: 1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combigan®
Description: 1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
Study: NCT05620121

Intervention type: PROCEDURE
Intervention: Surgery for Incisional hernias
Description: Laparoscopic and laparoscopic abdominal wall repair for Incisional Hernia with/without prosthetic material in urgent/emergent settings, with/without direct closure of the defect (IPOM and IPOM +).
Study: NCT06551844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir 400 mg
Description: This is an antiviral drug (an RNA dependent RNA polymerase inhibitor, with broad spectrum antiviral activity) currently approved for use in treatment for COVID-19 patients.~In this trial, its antiviral effectiveness on the early phase of dengue virus infection will be assessed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIS513 (a monoclonal antibody)
Description: VIS513 is an engineered humanised monoclonal antibody produced by recombinant DNA technology in a mammalian cell (i.e. Chinese hamster ovary) line. It was discovered in the USA by Visterra Inc and subsequently technology for manufacturing and further development was transferred to Serum Institute of India Pvt. Ltd., Pune, India. It has shown potent, specific neutralization of all four serotypes of DENV.
Study: NCT05627804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-moderate intensity exercise
Description: The participants will perform low-intensity cycling exercise at 90% lactate threshold under moderate hypoxia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sprint interval training
Description: The participants will perform sprint interval cycling exercise at a load of 7.5% bodyweight under moderate hypoxia.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional exercise
Description: The participants will perform bodyweight exercises under moderate hypoxia.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No exercise will be performed.
Study: NCT06290817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib combined with R-CDOP regimen
Description: All participants were treated with the orelabrutinib combined with R-CHOP regimen (O-RCDOP). The treatment plan involved orelabrutinib tablets at 150mg QD (once daily) from day 1 to day 21, Rituximab at 375mg/m2 on day 1; Cyclophosphamide at 750mg/m2 on day 1; Liposomal Doxorubicin at 30mg/m2 on day 0; Vincristine at 25mg/m2 on day 1 (maximum dose 40mg); and Prednisone at 100mg from day 1 to day 5. The treatment cycles were set every 21 days for a total of 6-8 cycles. Dose adjustments were made for elderly patients for Cyclophosphamide and Liposomal Doxorubicin based on age: 70-80% of the dose for those aged 70-80 years old, and 50-60% of the dose for those older than 80 years.
Study: NCT05967390

Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation
Description: One time for each day, lasting for three weeks.
Study: NCT06103474

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Magnetic Resonance Imaging (MRI)
Description: Lumbar Magnetic Resonance Imaging (MRI)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Magnetic Resonance Imaging (MRI)
Description: Lumbar Magnetic Resonance Imaging (MRI)
Study: NCT06545929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunobinop
Description: 1 tablet taken orally at bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match sunobinop
Description: 1 tablet taken orally at bedtime
Study: NCT05668559

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: The rTMS mode consists of a cluster stimulus delivered every 0.2 seconds (5 Hz), with each cluster stimulus consisting of three burst stimuli with a 50 Hz body frequency. The duration of a single stimulus was approximately 40 seconds, for a total of 600 pulses. Stimulation takes place bilaterally in the dorsolateral prefrontal cortex (DLPFC).~All enrolled patient in the rTMS group will receive 1 set simulation per day with an intersession interval (ISI) of over 30 minutes on postoperative day 1 to 5 after the surgery.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Shaman stimulation uses the same protocol (600 pulses per session, 3 sessions per set, ISI≥30 min, 3 sets) with the coil set at 90 against the skull on postoperative day 1 to 5 after the surgery.
Study: NCT04213911

Intervention type: RADIATION
Intervention: low-dose chest CT scan
Description: The low-dose chest CT scan is now commonly used as a quick, painless, and non-invasive approach to screen for lung cancer. The radiation exposure from one low-dose CT scan of the chest (1.5 mSv) is comparable to 6 months of natural background radiation for a person living in the US.

Intervention type: RADIATION
Intervention: low-dose chest CT scan
Description: The low-dose chest CT scan is now commonly used as a quick, painless, and non-invasive approach to screen for lung cancer. The radiation exposure from one low-dose CT scan of the chest (1.5 mSv) is comparable to 6 months of natural background radiation for a person living in the US.

Intervention type: DEVICE
Intervention: insertion of esophageal balloon
Description: The esophageal catheter is a flexible thin plastic tube with an air-filled balloon at the distal end. The tube will be placed through the nasopharynx after local anesthesia.

Intervention type: DEVICE
Intervention: insertion of esophageal balloon
Description: The esophageal catheter is a flexible thin plastic tube with an air-filled balloon at the distal end. The tube will be placed through the nasopharynx after local anesthesia.
Study: NCT05649371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: A multiphasic exercise prehabilitation program for alloHSCT candidates across each treatment phase, that includes behaviour change support
Study: NCT04877002

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sona Saliva C-19 Rapid Test
Description: Rapid Antigen diagnostic device performance comparative to RT-PCR
Study: NCT05983432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: The study includes 3 parts: Part 1 Dose escalation. Part 2 Dose Finding non-randomized and Part 3 Dose expansion randomized.
Study: NCT05309772

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Basophil activation test (BAT)
Description: Basophils and mast cells are the key drivers of food allergic reactions and anaphylaxis to foods. The study team have developed new tests that measure the reaction of mast cells and basophils by flow cytometry following stimulation with allergen, the BAT and the MAT:~• BAT uses fresh whole blood from patients added to allergen and antibodies in a test tube. The tube containing the allergic cells are then analysed one by one to estimate how many and how much express activation markers on their surface, CD63 and CD203c.~MAT uses a human mast cell line (LAD2 cells) which are human mast cells grown in the laboratory to which patients' plasma is added in order to mimic the patients' own mast cells. Sensitised LAD2 cells are then stimulated with allergen or controls and analysed by flow cytometry to assess the expression of the activation marker CD63 on the cell surface, similar to what happens in the BAT. Results of MAT will be considered only in cases of non-responding basophils.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Basophil activation test (BAT)
Description: Basophils and mast cells are the key drivers of food allergic reactions and anaphylaxis to foods. The study team have developed new tests that measure the reaction of mast cells and basophils by flow cytometry following stimulation with allergen, the BAT and the MAT:~• BAT uses fresh whole blood from patients added to allergen and antibodies in a test tube. The tube containing the allergic cells are then analysed one by one to estimate how many and how much express activation markers on their surface, CD63 and CD203c.~MAT uses a human mast cell line (LAD2 cells) which are human mast cells grown in the laboratory to which patients' plasma is added in order to mimic the patients' own mast cells. Sensitised LAD2 cells are then stimulated with allergen or controls and analysed by flow cytometry to assess the expression of the activation marker CD63 on the cell surface, similar to what happens in the BAT. Results of MAT will be considered only in cases of non-responding basophils.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Oral food challenge (OFC)
Description: Consumption of the food suspected of causing an allergic reaction in a medically supervised environment, starting with small amounts and progressively increasing the dose at regular intervals up to a cumulative dose corresponding to an age-appropriate portion of the food.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Oral food challenge (OFC)
Description: Consumption of the food suspected of causing an allergic reaction in a medically supervised environment, starting with small amounts and progressively increasing the dose at regular intervals up to a cumulative dose corresponding to an age-appropriate portion of the food.
Study: NCT05994807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC-806
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DC-806
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Description: Oral tablets
Study: NCT05037279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin: Strain Russian BCG-I
Description: * Induction: 80 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bacillus Calmette-Guerin: Strain TICE
Description: * Induction: 50 mg weekly for 6 weeks.~* Maintenance for intermediate AUA risk patients will be for 3 weeks at 3, 6, and 12 months.~* Maintenance for high AUA risk patients will be for 3 weeks at 3, 6, 12, 18, 24, 30 and 36 months.
Study: NCT06022575

Intervention type: PROCEDURE
Intervention: Telehealth integrated care
Description: Followed up in online Internet hospital, estimated and adjusted treatment accroding to clinical efficacy, and send individualized health education messages regularly.

Intervention type: PROCEDURE
Intervention: Conventional health care
Description: Followed up face-to-face in cardiacmetabolic clinics, estimated and adjusted treatment accroding to clinical efficacy, and conducted health education.
Study: NCT04810962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APP13007, 0.05%
Description: APP13007 eye drop, 0.05%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Vehicle Placebo for APP13007, 0.05%
Description: Matching vehicle placebo eye drop
Study: NCT05614076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conserved chalky white enamel margins of class V cavities
Description: during cavity preparation, we conserved chalky white enamel margins of class V cavities and then restored them with resin composite restorations,we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total removal of demineralized enamel margins of class V cavities
Description: during cavity preparation, we removed the total chalky white enamel margins of class V cavities and then restored them with resin composite restorations, we assessed the restorations with visual inspection using a mirror and explorer according to USPHS Criteria
Study: NCT06379126

Intervention type: DIAGNOSTIC_TEST
Intervention: Test thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM）
Description: Test TAT, PIC, tPAI·C and TM of blood of SIC patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Test thrombin-antithrombin complex（TAT）, α2-plasmin inhibitor-plasmin complex（PIC）, tissue plasminogen activator-inhibitor complex（tPAI·C） and thrombomodulin（TM）
Description: Test TAT, PIC, tPAI·C and TM of blood of SIC patients.
Study: NCT04954144

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Sensor
Description: As a virtual reality treatment method, leap motion sensor was integrated with laptop computer and participants played object capture, firefly, bee-batting games to improve performance based hand skills.
Study: NCT04527393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized oral morphine
Description: Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients with positive results of fentanyl test receive oral morphine 100μg/kg per dose, while patients with negative results receive oral morphine 500μg/kg per dose.
Study: NCT04954144

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Treatment Approach
Description: It is a method that tries to control sensorimotor components of muscle tone, reflexes, abnormal movement patterns, postural control, sensory-perception and memory problems with special techniques.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental Treatment Approach
Description: It is a method that tries to control sensorimotor components of muscle tone, reflexes, abnormal movement patterns, postural control, sensory-perception and memory problems with special techniques.
Study: NCT04527393

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional oral morphine
Description: Analgesic effectiveness is assessed using the Faces Scale by the parents every four hours from postoperative Day 1 to Day 10 (eg: 8:00, 12:00, 16:00, and 20:00, each day).~If the Faces Scale score \> 6, the child receive rescue oral morphine analgesia. Patients receive oral morphine 200μg/kg per dose.
Study: NCT04871113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3810109A
Description: GSK3810109A available as sterile aqueous solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3810109A
Description: GSK3810109A available as sterile aqueous solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3810109A
Description: GSK3810109A available as sterile aqueous solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3810109A
Description: GSK3810109A available as sterile aqueous solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK3810109A
Description: GSK3810109A available as sterile aqueous solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dolutegravir+lamivudine SOC regimen
Description: Dolutegravir+lamivudine regimen administered in consistence with investigator input and local guidelines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dolutegravir+lamivudine SOC regimen
Description: Dolutegravir+lamivudine regimen administered in consistence with investigator input and local guidelines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dolutegravir+lamivudine SOC regimen
Description: Dolutegravir+lamivudine regimen administered in consistence with investigator input and local guidelines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dolutegravir+lamivudine SOC regimen
Description: Dolutegravir+lamivudine regimen administered in consistence with investigator input and local guidelines

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dolutegravir+lamivudine SOC regimen
Description: Dolutegravir+lamivudine regimen administered in consistence with investigator input and local guidelines
Study: NCT04877964

Intervention type: DEVICE
Intervention: Ultrasound
Description: Using ultrasound with transverse median and paramedian sagittal oblique approach, the screens that show the target epidural space in the center are obtained and stored for evaluation.
Study: NCT05068115

Intervention type: PROCEDURE
Intervention: Clinical characteristics, diagnosis and treatment, survival status
Description: Describe the clinical characteristics, diagnosis and treatment, survival status and the trends of young breast cancer
Study: NCT04503460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol Xinafoate
Description: All participants will receive inhaled salmeterol xinafoate 50 μg twice in the morning and twice in the evening for 2 weeks; this will be followed by a 2-week washout period during which time no beta-agonists will be administered. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol Fluticasone
Description: Following the 2-week washout period, all participants will receive inhaled salmeterol xinafoate 50 μg combined with fluticasone propionate 250 μg twice in the morning and twice in the evening for 2 weeks. Participants will be asked to use 'as required' ipratropium bromide during this period when needed in place of short-acting beta agonists.
Study: NCT05880719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-assisted Music remediation
Description: These sessions of computer-assisted music remediation last 1h and are each divide in 4 parts :~* 15 minutes of music improvisation~* 20 minutes of harmony and rythm exercices~* 20 minutes of Lesson about the software and musical interfaces~* 5 minutes of debrief.
Study: NCT05340699

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Defocus Distributed Multi-point lens
Description: Wear DDM lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single vision lens
Description: Wear single vision lens
Study: NCT04841291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Foot Care Education (DFCE)
Description: Virtual simulation-based DFCE sessions on seven topics (the reasons for inspecting one's feet, risk factors and prevention strategies of diabetic foot ulcer, how to wash and moisturize feet, comfortable sock and shoe choices, what to look for, and what to do during feet inspection, how to trim fingernails, and how to maintain foot health) at University of Gondar computer lab for 30 minutes.
Study: NCT05509504

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-intensity online intervention
Description: The LiON in the current study is comprised of three core modules identified to be core areas of stress and needs of participants based on clinical experiences of the research team. The three modules include (1) stress management, (2) sleep and relaxation, and (3) problem-solving skills. Each module consists of four 1-on-1 sessions which will be conducted through online platforms (such as Zoom) that lasts for \~45 minutes. Participants will attend these sessions once a week.
Study: NCT06281249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound placement device
Description: Device to assist in placement of epidural procedure
Study: NCT05726084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subunit recombinant vaccine for the prevention of coronavirus infection
Description: solution for intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subunit recombinant vaccine for the prevention of coronavirus infection
Description: solution for intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subunit recombinant vaccine for the prevention of coronavirus infection
Description: solution for intramuscular injection, 0.5 ml

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: solution for intramuscular injection, 0.5 ml
Study: NCT05926713

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sarcojoint®
Description: All participants are administered Sarcojoint® containing leucinine 1 g, arginine 1.5 g, Vitamin D 7.5μg, chondroitin 400 mg, calcium 300 mg, and glucosamine 700 mg per package, and take 1 package twice a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: supervised exercise
Description: All participants are required to walk 6500 steps every day for 12 weeks, and the data are recorded by Xiaomi-smart-band.
Study: NCT03797612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivoligide Injection 660 mg/6 mL
Description: Single preoperative intrathecal injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 6 mL
Description: Single preoperative intrathecal injection
Study: NCT04938947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction Cuffs
Description: This intervention consists of inflatable cuffs that are designed to partially occlude veinous blood return from the lower extremities during resistance training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Intensity Resistance Training
Description: This intervention consists of performing low-intensity bilateral (both legs at the same time) leg extensions using 30% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Resistance Training
Description: This intervention consists of performing high-intensity bilateral (both legs at the same time) leg extensions using 80% of a participants 1 repetition maximum (the maximum weight an individual can complete 1 repetition with, but not 2) to volitional failure.